Title:
ADOPTIVE IMMUNITY THERAPY AS HUMAN TREATMENT METHOD
Document Type and Number:
Japanese Patent JPS62116518
Kind Code:
A
Abstract:
The present invention discloses a new approach to the therapy of cancer in humans based on the administration of lymphokine activated killer (LAK) cells and interleukin-2 (IL-2). Twelve patients with metastatic cancer who had failed standard available therapy were treated. LAK cells were generated from peripheral blood mononuclear cells obtained at multiple leukaphereses and incubated in the recombinant-derived lymphokine, IL-2. Following three to four days of incubation in IL-2, the resulting LAK cells were capable of lysing fresh tumor cells but not normal cells. These LAK cells were reinfused into the autologous patient, along with the intravenous administration of recombinant IL-2 every 8 hours. Patients received up to 90 doses of IL-2 and from 2.8 to 12.6x1010 activated cells from up to 14 sequential leukaphereses. Six patients showed objective regression of established cancer.
Inventors:
SUTEIIBUN EE ROOZENBAAKU
Application Number:
JP18671186A
Publication Date:
May 28, 1987
Filing Date:
August 08, 1986
Export Citation:
Assignee:
US HEALTH (US)
International Classes:
A61K35/14; A61K35/17; A61K38/00; A61K38/20; (IPC1-7): A61K35/14; A61K37/04
Domestic Patent References:
| JPS5829714A | 1983-02-22 | |||
| JPS58157723A | 1983-09-19 |
Attorney, Agent or Firm:
Takehiko Suzue
Previous Patent: JPS62116517
Next Patent: CELL METABOLISM ACTIVATING SUBSTANCE EXTRACTED FROM PLACENTA, EXTRACTION THEREOF AND METHOD FOR INAC...
Next Patent: CELL METABOLISM ACTIVATING SUBSTANCE EXTRACTED FROM PLACENTA, EXTRACTION THEREOF AND METHOD FOR INAC...